Large Roundworms and MS: New Evidence MS Is an Infectious Disease

MS is usually described as an autoimmune disease where the immune system “mysteriously” attacks the brain and spinal cord. Many studies now point to something more scientifically valid: MS often behaves like an infectious disease that begins in the gut and may involve chronic parasites such as large roundworms.

Large Roundworms that Infect Humans

Roundworms (nematodes) are among the most abundant animals on earth. They live in soil, water, plants, and almost every animal species. Many are harmless. Some are parasitic and live inside humans.

In people, large roundworms commonly:

• Live in the small intestine
• Travel through the liver, lungs, blood, and lymphatic system
• In some cases, invade the central nervous system (CNS)

Three roundworms are especially relevant when discussing MS:

 

Ascaris lumbricoides – Human Intestinal Roundworm

• Ascaris is the most common human worm infection worldwide.
• Adult females typically reach 8–14 inches or more in length.
• A single person can be infected with dozens if not hundreds of these worms at once.
• Each female can produce up to about 200,000 eggs per day.
  • These eggs leave the body in stool, contaminate soil, and can remain infectious for years.
• Ascaris worms live in the intestines but have a migratory phase through the body.
• Heavy infections can cause both digestive and systemic symptoms.

 

Toxocara – Dog and Cat Roundworm

• Toxocara species, especially Toxocara canis in dogs and T. cati in cats, are close relatives of Ascaris.
• In dogs and cats:
  • They develop into adult worms in the intestine.
  • They shed vast numbers of eggs in feces.
• In humans:
  • Larvae hatch from swallowed eggs, penetrate the gut wall, and migrate through organs such as the liver, lungs, eyes, brain, and spinal cord.

It is believed that Toxocara larvae “do not mature” into adults in humans and therefore never establish an egg‑laying intestinal infection. This claim has not been proven.

• People are rarely evaluated thoroughly for parasites.
• Parasite tests are not accurate.
• Adult worms in humans are almost never looked for systematically.

Because of this, the idea that Toxocara never matures in humans is best described as an assumption, not a definitively proven fact.

What is clear and documented:

• Toxocara larvae can cross the blood–brain barrier.
• They can trigger inflammatory damage in the CNS (neurotoxocariasis), including brain and spinal cord involvement.

 

Baylisascaris procyonis – Raccoon Roundworm

• Baylisascaris procyonis is a roundworm of raccoons that can infect humans.
• Its larvae can migrate through the brain and spinal cord and cause neural larva migrans.
• This leads to severe inflammation and demyelination.

Imaging findings:

• MRI scans in reported human cases show white‑matter changes.
• These changes can look very similar to demyelinating diseases such as MS or ADEM (acute disseminated encephalomyelitis).

Taken together, these organisms demonstrate that large roundworms are fully capable of:

• Entering the CNS
• Damaging myelin
• Producing lesions, demyelination and MS like symptoms 

 

The Gut–Brain Connection

Digestive Disease Before MS

Research into the early phase before formal MS diagnosis provides important clues. Large population‑based studies show many people who are eventually diagnosed with MS have digestive problems for years beforehand.

Canadian MS study (gastrointestinal conditions and MS):

A recent Canadian study looked at “gastrointestinal conditions in the years before MS diagnosis.

It found that the following conditions:

• Irritable bowel syndrome (IBS)
• Inflammatory bowel disease (IBD)
• Constipation
• Other GI disorders

were significantly more common in future MS patients for at least five years before diagnosis.

Other lines of evidence:

• Additional research has found that IBD is associated with an increased risk of later MS.
• Systematic reviews and meta‑analyses report that:
  • People with IBD have a higher lifetime risk of MS.
  • People with MS have a higher prevalence of IBD than would be expected by chance.

Taken together, these findings suggest:

• For many people, the disease process begins in the gut, not the brain.
• There is a prolonged period of intestinal dysfunction before the first neurological episode.
• Infections and parasites affecting the gut may play a central role in initiating or driving MS‑like pathology.

This fits well with an infectious model of MS where:

1. Parasites first colonize the intestines.
2. They disrupt the microbiome, gut and blood brain barriers.
3. Over time, they contribute to CNS damage and demyelination.

 

Childhood Dog Ownership and MS Risk

Several studies have examined whether childhood contact with pets influences MS risk later in life.

One study on pets in childhood found that:

• Having a dog at home between ages 0 and 10 was linked with about 1.9 times higher odds of MS later in life.
• Having a dog between ages 0 and 5 was linked with almost 2.7 times higher odds.

Another study followed women over many years and asked about animals they’d lived with:

• Being around animals at ages 10 to 14 was tied to about a 1.7‑times higher risk of MS.
• Specifically having a dog at ages 10 to 14 was linked to about a 1.8‑times higher risk.

A review that pooled several of these studies together concluded:

• Dogs in early childhood: roughly 2–3 times higher odds of MS.
• Dogs in early teen years: around 1.7–1.8 times higher risk.

Taken together with what is known about dog roundworms like Toxocara—dogs shedding parasite eggs into soil and children picking them up while they play—it makes sense that early dog contact could increase MS risk for some people.

 

Evidence Linking Toxocara Infection to MS

Several studies have directly examined whether Toxocara infection is more common in people with MS.

Case–control study from Iran (Neurology Asia):

• Researchers compared anti‑Toxocara antibodies in MS patients versus healthy controls.
• Results:
  • About 15% of people with MS had antibodies against Toxocara, compared with only about 1% of people without MS.
• This represents more than a 10‑fold difference between the two groups.
• The authors concluded that Toxocara infection may increase the risk of developing MS.

Meta‑analysis (Does Toxocara infection/exposure associate with MS risk?):

• A study published in Experimental and Therapeutic Medicine reviewed multiple datasets.
• It reported that individuals with positive anti‑Toxocara antibodies had an approximately 3 times higher lifetime risk of MS compared with those who were seronegative.

Broader review of the literature:

• A broader review concluded that:
  • Toxocara exposure is associated with MS.
  • Helminth infections in general may be an under‑recognized environmental factor in the disease.

These findings support the idea that roundworm infections are not incidental in MS—they may be part of the cause for at least a subset of patients.

 

How Toxocara Affects the Brain and Spinal Cord

Neurotoxocariasis refers to Toxocara infections involving the CNS. Experimental and clinical data show:

• Larvae can cross the blood–brain barrier.
• They can invade brain tissue and spinal cord tissue directly.
• The presence of larvae and their antigens triggers a local inflammatory reaction, often with:
  • Eosinophils
  • Granuloma formation – small inflamed lump
• It can cause serious nerve and brain problems, including:
  • Meningitis (infection around the brain and spinal cord)
  • Brain inflammation
  • Spinal cord inflammation
  • Seizures
  • Trouble with thinking and memory
  • Mood or behavior changes
  • Other nerve‑related problems

The damage observed arises from both:

1. Direct mechanical injury as larvae move through tissue.
2. Immune‑mediated inflammation surrounding the parasites.

This combination of:

• Chronic inflammation
• Structural injury

is very similar to what is seen in demyelinating diseases such as MS.

 

Baylisascaris: A Clear Example of Worm‑Induced Demyelination

Baylisascaris procyonis, the raccoon roundworm, provides one of the clearest demonstrations that roundworm infections can cause MS‑like brain lesions.

Classic infant case report (initially diagnosed as ADEM):

• An infant presented with progressive neurological decline.
• The initial diagnosis was ADEM, a demyelinating disease similar to MS.

Key points from that case:

• MRI scans showed:
  • Diffuse white‑matter abnormalities
  • Progressive demyelination
• Standard treatment with high‑dose corticosteroids produced no improvement.
• Further investigation identified Baylisascaris larvae in the CNS, confirming neural larva migrans as the true cause.

Imaging findings:

• The MRI appearance of Baylisascaris neural larva migrans can be virtually indistinguishable from MS lesions.
• The crucial difference is that in such cases, a parasitic infection is clearly identified as the driver.

 

Digestive and Neurological Symptoms of Roundworm Infections

The symptoms produced by Ascaris and other roundworms overlap significantly with symptoms commonly reported in MS.

During the lung migration phase of Ascaris, typical symptoms include:

• Persistent cough
• Shortness of breath
• Wheezing
• In some cases, coughing up blood

Once worms mature in the intestines, symptoms can broaden to include:

• Abdominal pain and bloating
• Constipation or bloody diarrhea
• Intestinal obstruction and vomiting in heavy infections
• Profound fatigue
• Brain fog
• Headaches
• Weakness and muscle cramps
• Nutrient deficiencies (including iron and vitamin B12)
• Visible worms in stool or vomit

Diagnostic challenges:

• Standard stool tests for ova and parasites are not accurate.
• Toxocara can be identified via blood tests for antibodies rather than direct visualization.
• Advanced tests such as PCR are rarely used in routine clinical practice.

As a result:

• Most people with significant parasite burdens may be told their tests are “normal.”
• This reinforces the misconception that worms are not involved.

 

The Helminth Therapy Story – Why It’s Misleading

Recently, the idea of deliberately infecting people with worms to treat autoimmune disease (helminth therapy) has attracted attention. The theory is that helminths “modulate” or “calm” the immune system.

MS trials have used species such as:

• Trichuris suis (pig whipworm)
• Hookworms

Results have been disappointing:

• Study sample sizes have been small.
• Follow‑up periods have been short.
• A trial of hookworm therapy in MS found no significant reduction in new MRI lesions compared with placebo over 36 weeks.
• Reviews of available studies conclude that any benefits are weak, inconsistent, or absent.

Well‑documented harms of helminths are often under‑emphasized. For example, hookworm infections can cause:

• Iron‑deficiency anemia
• Skin rash at the site where larvae penetrate the skin
• Cough and wheeze during lung migration
• Chronic abdominal pain, diarrhea, and weight loss
• Stunted growth and impaired cognitive development in children

From a biological standpoint:

• Parasitic worms survive by evading and suppressing host immunity.
• Immune suppression is in the parasite’s interest.

If MS is an infection‑driven disease:

• Adding more parasites is more likely to increase infection burden and inflammation than to resolve the underlying problem.

 

Levamisole: Antiparasitic Treatment That Improved MS

Researchers tested  the parasite drug levamisole in people with MS.

It was a double‑blind, placebo‑controlled trial conducted in early 1980s:

• 85 MS patients were randomly assigned to levamisole or placebo.
• The study was double‑blind and placebo‑controlled.
• Levamisole‑treated patients experienced:
  • Fewer relapses
  • Signs of stabilization compared with placebo
  • Disability significantly worsened in the placebo group over about two years, while it remained fairly stable in the levamisole group.

Four‑year double‑blind controlled study:

• A separate four‑year double‑blind controlled study evaluated levamisole in relapsing MS.
• Results reported:
  • Reduced relapse rates
  • Some slowing of disease progression
  • 36% of people taking levamisole had at least one relapse during the study, compared with 74% of those taking placebo.

These findings have largely been ignored, yet when viewed through an infectious lens, they suggest:

• When an antiparasitic drug (levamisole) is given, MS activity decreases.
• This aligns with the idea that treating underlying parasitic infections can reduce inflammation and improve outcomes.

 

What This Means for Understanding MS

When all of the evidence is considered together, a consistent picture emerges:

• Large roundworms such as Ascaris, Toxocara, and Baylisascaris can:
  • Infect humans
  • Invade the nervous system
  • Cause demyelinating lesions
• Toxocara infection is significantly more common among people with MS than among healthy controls.
  • Toxocara antibodies are associated with roughly a threefold increase in MS risk.
• Gastrointestinal disorders and gut inflammation frequently occur years before MS is diagnosed. This points to a gut‑first disease process.
• Childhood dog ownership, and thus higher Toxocara exposure, is linked to increased MS risk later in life.
• Antiparasitic therapy with levamisole improved MS outcomes in controlled clinical trials.

Taken together, this evidence supports the claim that MS is an infectious disease caused by a parasitic infestation. 

This does not mean:

• Every person with MS has the same infections.
• Or that treatment is simple or one‑size‑fits‑all.

It does mean:

• Looking for—and effectively treating—parasites is a crucial step in preventing progression and supporting recovery.

As research continues to evolve, large roundworms are likely to be recognized as central players in the cause of multiple sclerosis.

 

There are real solutions to recover from parasites today!

To restore health, we must focus on treating the cause of inflammation, which are parasites. First, identify the enemy (parasites), then support the body and treat the parasites while following a holistic approach. When parasitic infections are treated effectively, we can overcome inflammation or disease.

If you’re frustrated with the fact that our standard of care STILL doesn’t offer a real solution for treating MS and other diseases, then click on the link below to watch Pam Bartha’s free masterclass training and discover REAL solutions that have allowed Pam and many others to live free from MS and other diseases.

CLICK Here to watch Pam’s masterclass training

 

References: 

ROUNDWORM BIOLOGY & INFECTION

1. Ascaris lumbricoides Egg Production

CDC DPDx. Ascariasis. Centers for Disease Control and Prevention. Updated July 18, 2019. https://www.cdc.gov/dpdx/ascariasis/index.html

Key Findings: Female Ascaris lumbricoides worms produce approximately 200,000 eggs per day. Eggs are expelled in stool and can survive in soil for extended periods, maintaining infectivity for years. The life cycle involves larval migration through liver and lungs before returning to intestines where adults mature.

2. Ascaris lumbricoides Reproductive Biology

Animal Diversity Web. Ascaris lumbricoides (human intestinal roundworm). University of Michigan Museum of Zoology. https://animaldiversity.org/accounts/Ascaris_lumbricoides/

Key Findings: Females produce about 200,000 eggs daily with year-round breeding. Uteri may contain up to 27 million eggs at a time. The large fecundity and unusual egg resistance ensures parasite survival and transmission.

3. Ascariasis Clinical Overview

Gupta S, Chhina AS. Ascariasis. StatPearls [Internet]. Updated July 16, 2023. https://www.ncbi.nlm.nih.gov/books/NBK430796/

Key Findings: Approximately one billion people worldwide infected with Ascaris lumbricoides. Female worms produce up to 200,000 eggs daily. Stool exam can be negative during worm migration and maturation phase (approximately one month), contributing to diagnostic difficulty.

 

TOXOCARA & MS RISK

4. Toxocara Antibodies in Iranian MS Patients

Kuk S, Özgün S, Çiftdoğan DY. Toxocariasis and multiple sclerosis: A case-control study in Iran. Neurol Asia. 2014;19(3):283-287. http://neurology-asia.org/articles/neuroasia-2014-19(3)-283.pdf

Key Findings: Anti-Toxocara antibodies present in 14.7% of MS patients vs. 1.4% of healthy controls (p=0.004). More than 10-fold higher Toxocara seropositivity in MS group. Toxocara infection may significantly increase MS risk.

5. Toxocara Seroprevalence and 3× MS Risk

Etemadifar M, Nouri H, Mehrabi M, et al. Seroprevalence of anti-Toxocara antibody among multiple sclerosis patients: a case–control study. Acta Parasitol. 2019;64(4):850-855. doi:10.2478/s11686-019-00116-2. https://pmc.ncbi.nlm.nih.gov/articles/PMC7046906/

Key Findings: Anti-Toxocara IgG antibodies present in 28.6% of MS patients vs. 11.4% of controls (OR 3.1; 95% CI 1.26–7.63; p=0.02). Individuals with Toxocara seropositivity approximately three times more likely to develop MS throughout their life compared to seronegative individuals. Toxocara seroprevalence was 20% across all participants.

6. Meta-Analysis: Toxocara and MS Association

Nunes KP, Martins-Filho OA, Silva MC. Does Toxocara Infection/Exposure Associate with Multiple Sclerosis? A Systematic Review and Meta-Analysis. Pathogens. 2020;9(11):938. doi:10.3390/pathogens9110938. https://pmc.ncbi.nlm.nih.gov/articles/PMC7696196/

Key Findings: Meta-analysis showed anti-Toxocara IgG seroprevalence of 13.1% in MS patients vs. 4.8% in controls (pooled OR 3.01; 95% CI 1.46–6.21). Strong association between Toxocara exposure and MS development confirmed across multiple studies.

 

NEUROTOXOCARIASIS MECHANISM

7. Blood-Brain Barrier Impairment in Toxocara Infection

Wang W, Zhang W, Zhang F, et al. Blood-brain barrier impairment with enhanced SP, NK-1R, GFAP and Claudin-5 expression in Toxocara canis-infected mice. Parasite Immunol. 2008;30(10):457-464. doi:10.1111/j.1365-3024.2008.01043.x. https://pubmed.ncbi.nlm.nih.gov/18627507/

Key Findings: Toxocara canis larvae directly impair the blood-brain barrier in infected mice. Enhanced expression of substance P (SP), neurokinin-1 receptor (NK-1R), glial fibrillary acidic protein (GFAP), and altered Claudin-5 expression demonstrate mechanism by which Toxocara crosses into CNS and creates neuroinflammation.

8. Clinical Spectrum of Cerebral Toxocariasis

Deshayes S, Bonhomme J, De La Blanchardière A. Clinical spectrum of symptoms in cerebral Toxocariasis (Review). Exp Ther Med. 2021;21(6):521. doi:10.3892/etm.2021.9953. https://pmc.ncbi.nlm.nih.gov/articles/PMC8014984/

Key Findings: Neurotoxocariasis causes meningitis, encephalitis, myelitis, and neuropsychological disturbances mediated by inflammatory damage to nervous tissue. Larvae deposit in CNS creating chronic inflammation that damages myelin and neurons.

9. Toxocara Neuroinvasion and Brain Cytokine Changes

Gavignet B, Piarroux R, Cazenave L, et al. Neuroinvasion of Toxocara canis- and T. cati-larvae mediates dynamic changes in brain cytokine and chemokine profile. J Neuroinflammation. 2019;16(1):150. doi:10.1186/s12974-019-1542-8. https://pmc.ncbi.nlm.nih.gov/articles/PMC6637622/

Key Findings: Toxocara larvae neuroinvasion induces significant dynamic changes in brain cytokine and chemokine profiles including TNF-α, IL-6, MCP-1, and others. Demonstrates direct CNS invasion mechanism and subsequent neuroinflammatory cascade.

 

BAYLISASCARIS & DEMYELINATION

10. Baylisascaris Neural Larva Migrans Misdiagnosed as ADEM

Gavin PJ, Kazacos KR, Tan TQ, et al. Baylisascaris procyonis neural larva migrans in an infant in New York City. J Pediatric Infect Dis Soc. 2009;14(1):e9-e12. doi:10.1097/INF.0b013e3181845fc5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4205936/

Key Findings: Infant initially diagnosed with ADEM (acute disseminated encephalomyelitis) based on brain MRI showing progressive demyelination. Treated with high-dose corticosteroids without benefit. Eventually confirmed as Baylisascaris procyonis neural larva migrans. MRI findings indistinguishable from primary demyelinating diseases like MS/ADEM. Demonstrates roundworm larvae directly cause demyelination via mechanical injury plus damaging inflammatory response—neither protective nor curative.

 

GASTROINTESTINAL SYMPTOMS PRECEDE MS DIAGNOSIS

11. GI Conditions in MS Prodrome (5-Year Window)

Yusuf FLA, Zhu F, Evans C, et al. Gastrointestinal conditions in the multiple sclerosis prodrome. Mult Scler. 2024;30(1):73-82. doi:10.1177/13524585231218198. https://pmc.ncbi.nlm.nih.gov/articles/PMC10791028/

Key Findings: Large cohort study (British Columbia, 1996-2013) found GI-related physician visits and drug dispensations significantly more common in the 5 years before first demyelinating event versus matched controls. Conditions included gastritis, duodenitis, esophageal diseases, constipation, IBS, IBD. GI symptoms are early feature of MS prodrome, suggesting MS doesn’t begin in brain—it begins in gut. Supports dysregulation of gut-brain axis and potential parasitic origin.

12. IBD Associated with Subsequent MS Diagnosis

Lebwohl B, Roelstraete B, Khalili H, et al. Inflammatory bowel disease is associated with an increase in the incidence of multiple sclerosis: results from a large-scale, population-based cohort study. J Crohns Colitis. 2024;18(7):1093-1098. doi:10.1093/ecco-jcc/jjae022. https://pmc.ncbi.nlm.nih.gov/articles/PMC10953134/

Key Findings: Large German cohort showed significant association between IBD and subsequent MS diagnosis. Association stronger in men than women. Risk ratio of 1.91 for MS development in IBD patients. Provides evidence for epidemiological link and close pathophysiological connection between gut inflammation and CNS demyelination.

13. MS Prodrome Overview: GI and Mental Health Features

MS Canada Research Summary. Higher Rates of Mental Health and Gastrointestinal Issues Identified in MS Prodrome. MS Canada. July 6, 2025. https://mscanada.ca/ms-research/latest-research/mental-health-ms-prodrome-0

Key Findings: Dr. Helen Tremlett’s research identified MS prodromal period extending at least 5 years before clinical diagnosis. High rates of health service use for gastrointestinal issues and mental health conditions in 5-year window before MS diagnosis. Conditions pose significant burden early in disease course and may represent early manifestations of parasitic/infectious process.

 

DOG OWNERSHIP IN CHILDHOOD & MS RISK

14. Dog Exposure in Early Adolescence Increases MS Risk

Pohl D, Krone B, Rostasy K, et al. Animal exposure over the life-course and risk of multiple sclerosis: A case-control study within two cohorts of US women. Mult Scler Relat Disord. 2019;28:162-167. doi:10.1016/j.msard.2018.10.112. https://pubmed.ncbi.nlm.nih.gov/30471586/

Key Findings: Dog exposure in early adolescence associated with increased MS risk. Among 151 MS cases and 235 matched controls, dog exposure was most common animal exposure (79.5% cases vs. 72.3% controls). Animal exposure, specifically dog exposure, in early adolescence significantly associated with elevated MS risk. Supports Toxocara canis transmission from dogs to children as potential MS risk factor.

15. Childhood Pet Ownership Meta-Analysis

Ramagopalan SV, Valdar W, Dyment DA, et al. Childhood pet ownership and multiple sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2021;52:102976. doi:10.1016/j.msard.2021.102976. https://pubmed.ncbi.nlm.nih.gov/34090130/

Key Findings: Systematic review and meta-analysis of childhood pet exposure and MS development. Studies showed high heterogeneity but multiple case-control studies demonstrated association between childhood dog ownership and later MS risk. Studies acknowledge association but fail to identify parasitic mechanism (Toxocara transmission from dog definitive hosts to children).

16. Exposure to House Pets During Childhood and MS

Keyser JW, Zwanikken CP, van Oosten BW, et al. Multiple sclerosis and exposure to house pets during childhood and adolescence: a case-control study. Acta Neurol Scand. 1997;96(6):375-378. doi:10.1111/j.1600-0404.1997.tb00299.x. https://research.rug.nl/en/publications/multiple-sclerosis-and-exposure-to-house-pets-during-childhood-an/

Key Findings: Case-control study in Netherlands examining pet exposure during childhood/adolescence. Exposure during adolescence particularly associated with elevated MS risk later in life. Supports critical window of vulnerability to parasitic infections from household pets.

 

LEVAMISOLE (ANTIPARASITIC) STUDIES IN MS

17. Levamisole 3-Year Double-Blind Placebo Study (1982)

Gonsette RE, Demonty L, Delmotte P, et al. Modulation of immunity in multiple sclerosis: a double-blind levamisole-placebo controlled study in 85 patients. J Neurol. 1982;228(1):65-72. doi:10.1007/BF00313411. https://pubmed.ncbi.nlm.nih.gov/6184460/

Key Findings: 85 MS patients in double-blind placebo-controlled trial (mean 2-year follow-up). Placebo group showed significant deterioration in neurological function and disability. Levamisole group remained fairly stable. Annual relapse rate and disability score more stable in levamisole-treated patients with severe disability. Suggests long-term levamisole (antiparasitic/immunomodulator) therapy useful in MS. Supports parasitic infection driving MS pathology.

18. Levamisole 4-Year Study: 51% Relapse Reduction

Olsson JE, Broman T, Hårdemark HG, et al. Four year double-blind controlled study of levamisole in multiple sclerosis. Acta Neurol Scand. 1990;82(5):347-350. doi:10.1111/j.1600-0404.1990.tb04499.x. https://pubmed.ncbi.nlm.nih.gov/2081685/

Key Findings: 41 patients with definite MS in stationary phase; 22 treated with levamisole 150-200mg weekly for 4 years, 19 with placebo. Levamisole significantly reduced MS patients with acute relapse: 8/22 levamisole patients (36%) vs. 14/19 placebo patients (74%) experienced exacerbations (statistically significant). Absolute reduction of 38%; relative risk reduction of 51%. Direct antiparasitic treatment improves MS outcomes, suggesting MS pathology driven by parasitic infection rather than primary autoimmune dysfunction.

 

HELMINTH THERAPY TRIALS (FAILED TO SHOW BENEFIT)

19. Hookworm Therapy Trial Shows No MRI Benefit

Fleming JO, Isaak A, Lee JE, et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult Scler. 2011;17(6):743-754. doi:10.1177/1352458511398054. https://pubmed.ncbi.nlm.nih.gov/21372112/

Key Findings: Small hookworm trial in MS patients with limited follow-up (36 weeks). Primary outcome measure (total new MRI lesions) showed no significant difference between hookworm and placebo groups. Findings inconclusive. Consistent pattern across helminth therapy trials: fail to demonstrate strong clinical or MRI benefits despite theoretical “immune modulation” claims.

20. Comprehensive Helminth Therapy Reviews

Multiple systematic reviews and meta-analyses 2018-2022.

Key Findings: Helminth therapy trials in MS show weak or inconsistent benefits. Parasite accumulation can provoke inflammatory responses (opposite of theoretical benefit). May worsen MS symptoms. No strong clinical or MRI benefits demonstrated in well-designed trials. Hygiene hypothesis and “immune modulation” by parasites unsupported by evidence.

 

HOOKWORM HARMS

21. Hookworm Infection Harms in Children

Jonker FAM, Calis JCJ, Phiri K, et al. Hookworm infection in infants: a case report and review of literature. Parasitol Int. 2012;61(3):408-412. doi:10.1016/j.parint.2012.02.001. https://pmc.ncbi.nlm.nih.gov/articles/PMC7871578/

Key Findings: Hookworm infection causes iron deficiency anemia, itchy rash at larval skin penetration site, respiratory symptoms during lung migration (cough, wheezing, breathing difficulty), abdominal pain, weight loss, diarrhea, appetite loss. In children: retarded growth, impaired mental development, cognitive deficits.

22. Hookworm Disease Pathophysiology

HealthyChildren.org. Hookworms. American Academy of Pediatrics. Updated December 31, 2005. https://www.healthychildren.org/English/health-issues/conditions/from-insects-animals/Pages/Hookworms.aspx

Key Findings: Hookworms attach to intestinal wall and consume blood, causing chronic iron deficiency anemia. Can lead to protein malnutrition, impaired physical growth, and cognitive impairment in children. Disease-causing parasites with well-documented harms—not therapeutic agents.

 

ADDITIONAL NEUROTOXOCARIASIS EVIDENCE

23. Cerebral Toxocariasis and Neurodegenerative Disorders

Mahdi NK, Al-Sadoon IA. Cerebral Toxocariasis: Silent Progression to Neurodegenerative Disorders. Biomed Res Int. 2015;2015:854292. doi:10.1155/2015/854292. https://pmc.ncbi.nlm.nih.gov/articles/PMC4462679/

Key Findings: Toxocara larvae in CNS can persist for years creating chronic neuroinflammation. May lead to silent progression toward neurodegenerative disorders. Chronic cerebral toxocariasis creates persistent inflammatory milieu that damages neurons and myelin over time.

24. Toxocara Worsens Experimental Autoimmune Encephalomyelitis (MS Model)

Reyes JL, Espinoza-Jiménez AF, Terrazas LI. Toxocara canis infection worsens the course of experimental autoimmune encephalomyelitis in mice. Parasite Immunol. 2022;44(11):e12941. doi:10.1111/pim.12941. https://pmc.ncbi.nlm.nih.gov/articles/PMC11010483/

Key Findings: In mouse model of MS (experimental autoimmune encephalomyelitis/EAE), Toxocara canis infection worsened disease course rather than improving it. Directly contradicts “helminth therapy” hypothesis. Parasitic infection exacerbates neuroinflammation and demyelination rather than providing immune modulation benefit.